U.S.-listed shares of BeiGene rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.
BGNE stock had pared most of the gains and was last trading 1.7% higher as of 1010 ET.
BGNE's quarterly revenue of $341.57M rose 127.7% Y/Y and beat estimates by $30.5M. However, Q2 GAAP earnings per American depositary share of -$5.56 missed expectations by $1.45.
The bulk of BGNE's Q2 sales came from product revenue of $304.5M (vs. $138.6M last year), which included:
- Global sales of BeiGene's (BGNE) cancer drug Brukinsa, which came in at $128.7M, a significant increase from $42.4M last year.
- Sales of BGNE's other cancer medication, tislelizumab, of $104.9M in China, compared to $74.9M last year.
- Sales of products in-licensed from Amgen (AMGN) of $29.5M in China vs. $3.3M a year ago.
- Sales of products in-licensed from Bristol-Myers Squibb (BMY) of $23.4M in China, a Y/Y gain from $13.4M.
“We made significant progress in our mission to reach far more cancer patients with innovative and affordable medicines, with growth in product revenues across our portfolio, driven primarily by our internally developed medicines, Brukinsa and tislelizumab," BeiGene CEO John Oyler said in the earnings report.
Up to Wednesday's close, BGNE American depositary shares have lost 37.4% YTD.